⌘K
t
Destiny Pharma plc announced on May 25, 2023, that its Annual General Meeting was held earlier the same day. At this meeting, all resolutions proposed to shareholders were duly passed.
| Date | 25 May 2023 |
| Time | 12:23:40 |
| Category | AGMs and other meetings |
| ID | 6865A |
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Result of Annual General Meeting
Brighton, United Kingdom - 25 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.
The full text of each resolution was included in the notice of the meeting which was made available on the Company's website and posted to shareholders on 27 April 2023. The results for the resolutions will shortly be available on the Investors' section of the Company's website, www.destinypharma.com.
For further information, please contact:
Destiny Pharma plc
Dr Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 203 922 0891
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the Company, please visit https://www.destinypharma.com